Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $10.0152W HIGH $42.12
Volume
6.60 K
Value Traded
75.84 K
Short % Float
0.82%
-1.45%Week
-12.46%1 Month
+14.93%3 Month
+60.15%6 Month
-99.13%5 Year
-13.46%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
63.49 M
EPS (TTM)
-7.57
P/E Ratio
-
Ent. Value
28.55 M
Total Shares
2.91 M
Float Shares
690.00 K
Insiders
76.20%
Institutions
0.37%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
APLM Catalyst Timeline
Dated clinical, regulatory and corporate events for Apollomics Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Apollomics Inc.
155Total events
3Upcoming
50Tier-1 (high impact)
2019 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Partnership / LicenseAPL-101FiledCorporate
Initiated dispute resolution process with Launxp International Co., Ltd.
▲Partnership / LicenseAPL-101FiledCorporate
Terminated Collaboration and License Agreement with Launxp International Co., Ltd.
non-small cell lung cancer and other advanced tumors with c-Met alterationssource ↗
▲Enrollment UpdateAPL-101FiledTrial
Over 282 subjects enrolled in SPARTA study as of April 2026
Solid tumors with MET alterationssource ↗
▲Interim AnalysisAPL-101FiledTrial
Interim efficacy and safety data from SPARTA and KUNPENG trials demonstrated efficacy in MET Exon14 skipping NSCLC
NSCLC with MET Exon14 skipping mutationsource ↗
▼Debt Royalty FinancingCorporate
Apollomics enters into $2.0 million convertible promissory note with CEO
▲IP Litigation RulingIP / Competition
Settlement agreement reached in Cayman Litigation with TWVC
●Enrollment UpdateAPL-101FiledTrial
SPARTA trial continues enrollment and operations
multiple tumor typessource ↗
◆Timing GuidanceAPL-101FiledPresentation
Plans to use China approvals to file for regulatory approvals in Southeast Asia, Middle East, and other markets
MET-amplified NSCLC and GBMsource ↗
▲FDA Feedback ReceivedFDA Meeting
Nasdaq determined Apollomics meets continued listing requirements; hearing cancelled
▲AdCom CancelledAdvisory Committee
Nasdaq hearing cancelled after company found compliant for continued listing
▲Program DiscontinuationAPL-101FiledCorporate
Planned termination of SPARTA trial reversed; trial continues
multiple tumor typessource ↗
▼Program DiscontinuationAPL-101FiledCorporate
Expected discontinuation of APL-101 clinical trials announced, but later reversed
multiple tumor typessource ↗
▼Restructuring LayoffsCorporate
Company announced intent to seek shareholder approval to wind up business and discontinue SPARTA trials
▼Program DiscontinuationAPL-101FiledCorporate
Expected to discontinue SPARTA clinical trials for vebreltinib, but later reversed
NSCLC and other advanced tumors with c-Met alterationssource ↗
◆Runway Guidance UpdateCorporate
Current capital resources expected to fund operations into Q3 2025
▲Partnership / LicenseAPL-101FiledCorporate
Partnership with LaunXP to expand clinical dataset for vebreltinib combination therapy with EGFRi
NSCLCsource ↗
▲Partnership / LicenseAPL-101FiledCorporate
Development and commercialization agreement with LaunXP for vebreltinib in combination with EGFRi in Asia
NSCLCsource ↗
▲Partnership / LicenseAPL-101FiledCorporate
Development and commercialization agreement with LaunXP for vebreltinib in combination with EGFR inhibitor in Asia (ex-China)
NSCLC (combination with EGFR inhibitor)source ↗
▲NMPA NDA ApprovalAPL-101FiledEx-US Regulatory
Vebreltinib approved by NMPA for three indications
METex14 skipping NSCLC, MET-amplified NSCLC, PTPRZ1-MET fusion high-grade gliomassource ↗
▲NMPA NDA ApprovalAPL-502Ex-US Regulatory
APL-502 (benmelstobart) approved by NMPA for three indications
extensive-stage small cell lung cancer, recurrent/metastatic endometrial cancer, late-stage unresectable or metastatic renal cell carcinomasource ↗
▲Trial InitiationAPL-101FiledTrial
Relaunch of previously paused vebreltinib clinical program (SPARTA study)
Solid tumors with MET alterationssource ↗
●Enrollment UpdateAPL-101FiledTrial
Continued enrollment in SPARTA cohort for c-MET amplified NSCLC
NSCLC with c-MET amplificationsource ↗
▼Topline ReadoutUproleselanClinical Data
Top-line results for Phase 3 bridging trial of uproleselan in China
relapsed or refractory acute myeloid leukemiasource ↗
▼Program DiscontinuationUproleselanCorporate
Wrapping up uproleselan program due to negative results
relapsed or refractory acute myeloid leukemiasource ↗
▲Poster PresentationAPL-101FiledPresentation
Poster presentation at ESMO 2024 of vebreltinib efficacy and safety data in NSCLC with METex14 skipping mutations
non-small cell lung cancer with METex14 skipping mutationssource ↗
◆Oral PresentationPresentation
Apollomics management presenting at H.C. Wainwright 26th Annual Global Investment Conference
◆Oral PresentationPresentation
Apollomics management presenting at Canaccord Genuity 44th Annual Growth Conference
Past FDA Catalysts and PDUFA Decisions
How APLM actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-12-31 | vebreltinib (APL-101) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D20 / 100
Pipeline Score
$26M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.4x
rNPV / MCap
Top 94%
Micro Cap(rank 619 of 658)
Percentile Rank
Apollomics Inc. faces pipeline headwinds (20/100), with $562M risk-adjusted pipeline value, led by APL-101 in Solid Tumors (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| APL-101 Small moleculeNCT03175224 | Solid Tumors | Phase 2 | RECRUITING | 497 | Nov 30, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every APLM program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| vebreltinib | non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-27 | over 282 subjects have enrolled in the SPARTA study; over 600 patients and 170 healthy volunteers have been dosed with vebreltinib in clinical trialsRead More | Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business ProgressRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| LIN PETER KUAN-HOWOfficer (Chief Financial Officer) | Option | 10,000 58,979 held | $0.00 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in APLM
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % (-100 %) | 1.81 M | 8.57 M |
APLM Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How APLM ranks across every disease it competes in
Competitive Position is a premium feature
See how APLM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAPLM News
-APLM
Aug 11, 2026▼ -6.1%on this news· ran to +30% by day 3
Apollomics Announces $10 Million Private Placement Transaction
Apollomics Inc. has announced a $10 million private placement transaction aimed at advancing its late-stage clinical development of oncology drug candidates. The funding will support the company's efforts to tackle difficult-to-treat and treatment-resistant cancers. This financial boost is expected to enhance Apollomics' capabilities in the biopharmaceutical sector.
Read more →-APLM
Jul 13, 2026▼ -25%on this news
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Apollomics Inc. announced that it has regained compliance with Nasdaq's Market Value of Listed Securities requirement. The company was previously notified of non-compliance due to a market value drop but has since maintained a value above $35 million for the required 10-day period. This matter is now officially closed, allowing Apollomics to continue its operations on the Nasdaq Capital Market.
Read more →-APLM
Jun 24, 2026▲ +7.3%on this news
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics Inc. has received a notice from Nasdaq indicating non-compliance with the minimum market value requirement. The company has a 180-day period to regain compliance or face delisting. Separately, Apollomics terminated its collaboration with Launxp International due to a breach, regaining rights to its lead asset, vebreltinib, in Asia.
Read more →-APLM
Apr 27, 2026Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics reported its financial results for 2025, highlighting the ongoing Phase 2 studies of vebreltinib, a promising c-MET inhibitor. The company plans to submit an IND application for accelerated approval in 2027. Despite a significant net loss, Apollomics has made strides in cost reduction and management restructuring, aiming to enhance its clinical pipeline.
Read more →-APLM
Apr 1, 2026▼ -7.1%on this news
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Inc. has announced a $2.0 million bridge financing through an unsecured Convertible Promissory Note with its CEO, Mr. Hung-Wen Chen. The funds are intended to provide necessary working capital for clinical development programs and corporate operations. This note features a 0% interest rate and will convert into equity during a future financing round. The company has highlighted potential risks associated with its forward-looking statements, which could affect its plans and strategies.
Read more →-APLM
Dec 22, 2025▲ +10.6%on this news
INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Unaudited Condensed Consolidated Interim Statements of Financial Position as of
Apollomics Inc. released its unaudited condensed consolidated interim financial statements for the first half of 2025, revealing a continued net loss of $12,536. Despite generating revenue of $8,500, the company's total assets have decreased to $11,119, leading to negative equity of $(4,398). High research and development expenses, alongside other liabilities, signal ongoing financial challenges for the clinical-stage biotechnology company focused on oncology therapies.
Read more →-APLM
Dec 22, 2025▲ +10.6%on this news
Apollomics Reports First Half 2025 Financial Results
Apollomics Inc. reported its financial results for the first half of 2025, revealing a net loss of $12.5 million, a substantial decrease from $35.2 million in the same period last year. The company noted that its cash reserves are adequate to sustain operations through the third quarter of 2026, despite a significant drop in cash and equivalents from the previous year. R&D expenses saw a dramatic decline, while G&A expenses did increase compared to 2024.
Read more →-APLM
Nov 19, 2025Apollomics Inc. ("Apollomics" or the "Company") (Nasdaq: APLM) announced today entering into a settlement agreement (the
Apollomics Inc. (APLM) has entered into a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited, fully resolving previous litigation in the Cayman Islands concerning the redemption of preferred shares prior to a merger. The company will pay TWVC $5 million in installments over two years, along with approximately $879,757.78 for legal expenses, significantly lowering potential damages from an initial claim of $40 million. TWVC will withdraw all claims against Apollomics, and the agreement is pending court approval.
Read more →-APLM
Nov 19, 2025Apollomics Announces Settlement of Cayman Litigation
Apollomics Inc. has announced a settlement agreement with TWVC Goldlink Partners Investment Limited and TWVC Panglin Group Investment Limited regarding a litigation case that arose from a request for redemption of preferred shares prior to the company's merger with Maxpro Capital Acquisition Corporation. The settlement, which resolves all claims, involves Apollomics agreeing to pay a total of $5 million plus legal expenses over two years. This is a significant reduction from the original $40 million claim filed in the Grand Court of the Cayman Islands.
Read more →-APLM
Nov 18, 2025▼ -14.5%on this news· ran to -33% by day 3shared move
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Apollomics Inc. has announced changes to its Board of Directors, following the resignation of Mr. Po-Jen Hsueh, which was not due to any disagreement. Dr. Ya-Chi (Claudia) Huang has been appointed as his replacement and will serve on the Audit Committee and Nominating and Corporate Governance Committee. Dr. Huang brings significant experience in biotechnology investment and corporate governance, having previously served in key roles at Maxpro Ventures and Diamond Biofund.
Read more →-APLM
Oct 15, 2025Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Apollomics Inc. announced that it has received confirmation from Nasdaq that it complies with continued listing requirements, leading to the cancellation of a scheduled appeal hearing regarding a prior delisting notification. This decision allows Apollomics' securities to remain listed and continue trading on the Nasdaq Stock Market. The company is focused on developing oncology therapies, including its lead program vebreltinib.
Read more →-APLM
Oct 14, 2025▲ +5.8%on this news· ran to +73% by day 1shared move
Apollomics, Inc. Company Operational Continuity Update
Apollomics Inc. has announced an operational update, reversing its previous decision to wind up operations after securing $4.1 million in funding. The company is committed to continuing its global Phase 2 trial of APL-101 (vebreltinib) and has appointed a new management team. Apollomics aims to leverage its clinical developments and pursue regulatory submissions in various markets.
Read more →-APLM
Sep 25, 2025▲ +5.8%on this news· ran to +73% by day 1shared move
Apollomics Announces Completion of Filing of Appeal of Nasdaq Delisting Order
Apollomics Inc. has completed its appeal application against a Nasdaq delisting order and requested a hearing. The company is optimistic about its chances but acknowledges the uncertainty of the outcome. Additionally, litigation proceedings in the Cayman Islands are currently stayed, allowing the company to focus on its appeal and ongoing clinical trials.
Read more →-APLM
Sep 21, 2025▲ +5.8%on this news· ran to +73% by day 1shared move
Apollomics Announces Receipt of Nasdaq Delisting Notification, and Will Appeal to Retain Nasdaq Listing
Apollomics Inc. received a delisting notification from Nasdaq, which deemed the company a 'public shell' due to perceived operational deficiencies. The company plans to appeal this decision while asserting its activity in developing oncology therapies, specifically vebreltinib. Despite recent challenges, including a past intention to wind up business, Apollomics has restructured operations following a recent investment. A formal appeal will be filed by September 25, 2025, as the company seeks to maintain its Nasdaq listing.
Read more →-APLM
Aug 28, 2025▼ -32.8%on this news
Apollomics Inc. (incorporated in the Cayman Islands as an exempted company with limited liability) (Nasdaq: APLM) 989 E. Hillsdale Blvd., Suite 220 Foster City, California 94404 NOTICE OF EXTRAORDINARY GENERAL MEETING OF
Apollomics Inc. has called for an extraordinary general meeting of shareholders to take place on September 4, 2025. The primary agenda item is the Winding Up Proposal, which aims to dissolve the company due to its inability to sustain operations or meet financial obligations. Shareholders are being urged to vote on the proposal, as well as an Adjournment Proposal, which would provide time to gather sufficient votes for the Winding Up. The Board believes this is necessary for the best recovery for the company's creditors.
Read more →-APLM
Apr 3, 2025▼ -10.6%on this news· ran to -24% by day 1
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics Inc. reported its financial results for the fiscal year 2024, highlighting significant clinical updates and business progress. The company announced a partnership with LaunXP to enhance the clinical dataset for its drug vebreltinib, which shows promise in treating non-small cell lung cancer. Additionally, preliminary results for various tumor types indicate potential efficacy, although there are inherent risks and uncertainties in clinical development and commercialization.
Read more →-APLM
Mar 31, 2025▼ -18.5%on this newsshared move
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics has entered a development and commercialization agreement with LaunXP for vebreltinib, a c-Met inhibitor, in combination with an EGFR inhibitor for NSCLC treatment in Asia. The agreement includes an upfront payment of $10 million, with additional milestone payments possible. Both companies aim to improve patient outcomes by delaying EGFRi resistance.
Read more →About Apollomics Inc.
HeadquartersFoster City
Founded2015
BIOPHARMAWATCH ELITE PLUS
Trade the next APLM catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime